EUVIMEDEUVIMED entdecken
Crossref

Kidney transplant from HCV viremic donors to HCV‐negative recipients and risk for de novo donor specific antibodies and acute rejection

Reem Daloul, Kalathil Sureshkumar, Kendra Schnelle, Lauren Von Stein iD, April Logan, Todd Pesavento

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Reem Daloul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, Pennsylvania,…. Hauptthemen laut MEDLINE: Kidney Transplantation, Hepatitis C. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kidney transplantation from HCV‐viremic donors into uninfected recipients is associated with excellent short‐term outcomes. However, concerns regarding an increased risk for the development of de novo donor specific antibodies (DSA) and acute rejection have been raised in single center reports.

Methods

A retrospective study of HCV‐negative kidney‐only transplant recipients between 2018 and 2020. Patients were grouped based on the donor HCV status into group 1; HCV‐viremic donors, and group 2; HCV‐negative donors. Inverse probability of treatment weighting (IPTW), with weights derived from the propensity score, were used to estimate the effect of donors’ HCV‐viremia on the recipients. The primary objective was to compare the 1‐year incidence of de novo DSA. Secondary outcomes included group comparison of the incidence of biopsy proven acute rejection (BPAR), 1‐year patient and allograft survival, and 1‐year renal allograft function.

Results

A total of 71 patients were included in the HCV NAT+ group, and 440 in the HCV‐ negative group. One‐year incidence of de novo DSA was higher in the HCV NAT+ group in the IPTW weighted analysis (19% vs. 9%, p = .02). In the unweighted analysis, BPAR occurred in 7% of recipients in the HCV NAT+ group, compared to 3% in the control group ( p = .06). However, due to the low event rate in the in the IPTW weighted groups, a statistical significance test could not be performed. Average estimated GFR was higher in the HCV‐viremic group at 3 months (61 vs. 53 ml/min/1.73 m 2 p = .002), but comparable at 6 (59 vs. 56 ml/min/1.73 m 2 , p = .31) and 12 months (60 vs. 55 ml/min/1.73 m 2 , p = .07). Patient and allograft survival were comparable between the two groups.

Conclusion

Kidney transplant from HCV‐viremic donors was associated with an increased risk for the development of post‐transplant de novo DSA in the first year after transplantation, but no difference in patient and graft survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationHepatitis CHumansRetrospective StudiesViremiaTissue DonorsAntibodiesTransplant RecipientsGraft SurvivalGraft Rejection

Stichwörter der Autor:innen

Kidney transplantacute rejectiondonor specific antibodyhepatitis Crejection

Substanzen

Antibodies

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Division of Transplantation, Department of Surgery, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Division of Nephrology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.

ORCID-Profile: Lauren Von Stein

Zitieren

APA

Daloul, R., Sureshkumar, K., Schnelle, K., Von Stein, L., Logan, A., & Pesavento, T. (2023). Kidney transplant from HCV viremic donors to HCV‐negative recipients and risk for de novo donor specific antibodies and acute rejection. Clinical Transplantation. https://doi.org/10.1111/ctr.14895

Vancouver

Daloul R, Sureshkumar K, Schnelle K, Von Stein L, Logan A, Pesavento T. Kidney transplant from HCV viremic donors to HCV‐negative recipients and risk for de novo donor specific antibodies and acute rejection. Clinical Transplantation. 2023. doi:10.1111/ctr.14895

BibTeX
@article{Daloul2023,
  author = {Daloul, Reem and Sureshkumar, Kalathil and Schnelle, Kendra and Von Stein, Lauren and Logan, April and Pesavento, Todd},
  title = {Kidney transplant from HCV viremic donors to HCV‐negative recipients and risk for de novo donor specific antibodies and acute rejection},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14895}
}
Kostenlos starten →